Pathos logo

Pathos

AI-enabled drug development built for patients

96 employees · est. 2022 · Chicago, United States

VS
Scailyte logo

Scailyte

True precision medicine through single-cell science.

18 employees · est. 2017 · Basel, Switzerland

Scailyte is the older company (2022 vs 2017); Pathos is the larger of the two.

Side-by-Side Comparison

Pathos Scailyte
Founded
2022 2017 older
Headquarters
Chicago, United States Basel, Switzerland
Employees
96 larger 18
Industry
Not tracked yet AI, Biotechnology, Health Care
Funding Stage
Series D Series A
Total Funding
$365.00M $21.12M
Funding Rounds
3 9
Services
AI-driven Clinical Trials, Precision Therapy Discovery, Data Modeling for Oncology, Biopharmaceutical Collaboration Autoimmune Foundation Model development, Advanced patient endotyping, Predictive disease modeling, Biomarker assays co-development, Pharma partnership facilitation
Target Customers
Biopharmaceutical Companies, Clinical Researchers, Healthcare Providers, Investors in Biotech Pharmaceutical companies, Biotech firms, Clinical researchers, Healthcare providers, Decision-makers in precision medicine
Taxonomy
AI-enabled Drug Development, Precision Oncology, Multimodal Patient Data, Oncology, Biomarker-driven Clinical Execution, Clinical Trials, Drug Discovery, Cancer Biology, Computational Biology, Biopharma, Model-driven Hypotheses, Precision Medicine AI-driven Biomarker Discovery, Single-cell Omics, ScaiVision Platform, Oncology, Auto-immunity, Precision Medicine, Biomarker Signatures, Clinical Partnerships, Biotech Collaboration, Pharma Collaboration, Drug Development, Phenotypic Biomarker Discovery, Molecular Profiles, Disease Biology
Website
pathos.com scailyte.com
Pathos logo

About Pathos

Pathos, founded in 2022 and headquartered in the United States, is a clinical-stage, AI-enabled precision oncology biotech. Its slogan, "AI-enabled drug development built for patients", encapsulates its mission to revolutionize the biopharma sector. The company is pioneering the integration of AI w...

Scailyte logo

About Scailyte

Scailyte, founded in 2017 and headquartered in Basel, Switzerland, is a leader in AI-driven biomarker discovery from single-cell omics data. The company’s proprietary AI platform, ScaiVision, enables the analysis of over 60 million single-cell profiles. This capability positions Scailyte at the fore...

We will tell you when either one moves

BounceWatch watches Pathos and Scailyte for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.

Watch both — free

Funding, hiring, leadership and stack changes at Pathos and Scailyte — by email.

Frequently Asked Questions

Pathos — AI-enabled drug development built for patients. Scailyte — True precision medicine through single-cell science. . Both companies operate in related markets but may differ in funding stage, team size, and product focus.
Pathos has raised $365.00M while Scailyte has raised $21.12M.
Pathos and Scailyte operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare Pathos with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at Pathos on 15 Jun 2026, and Scailyte on 11 Mar 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

One analytics cookie (Google Analytics). Cookie Policy